Build Your Comparison

Side-by-side financial analysis
TRNS logo
TRNS
TMO logo
TMO
JPM logo
JPM
DHR logo
DHR
A logo
A
Try popular comparisons:

Stock Comparison

TRNS vs TMO vs JPM vs DHR vs A

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TRNS
Transcat, Inc.

Industrial - Distribution

IndustrialsNASDAQ • US
Market Cap$852M
5Y Perf.+252.9%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$174.42B
5Y Perf.+29.5%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+241.0%
DHR
Danaher Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$127.47B
5Y Perf.+14.9%
A
Agilent Technologies, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$36.67B
5Y Perf.+46.9%

TRNS vs TMO vs JPM vs DHR vs A — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TRNS logoTRNS
TMO logoTMO
JPM logoJPM
DHR logoDHR
A logoA
IndustryIndustrial - DistributionMedical - Diagnostics & ResearchBanks - DiversifiedMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$852M$174.42B$896.00B$127.47B$36.67B
Revenue (TTM)$333M$45.20B$280.33B$24.78B$7.23B
Net Income (TTM)$7M$6.86B$57.05B$3.69B$1.41B
Gross Margin32.6%39.4%60.0%60.7%53.0%
Operating Margin4.1%17.8%25.9%21.0%21.5%
Forward P/E51.9x18.9x14.4x21.3x21.4x
Total Debt$129M$40.85B$942.38B$18.42B$3.35B
Cash & Equiv.$5M$9.86B$343.34B$4.62B$1.79B

TRNS vs TMO vs JPM vs DHR vs ALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TRNS
TMO
JPM
DHR
A
StockJun 20Jun 26Return
Transcat, Inc. (TRNS)100352.9+252.9%
Thermo Fisher Scien… (TMO)100129.5+29.5%
JPMorgan Chase & Co. (JPM)100341.0+241.0%
Danaher Corporation (DHR)100114.9+14.9%
Agilent Technologie… (A)100146.9+46.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: TRNS vs TMO vs JPM vs DHR vs A

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Transcat, Inc. is the stronger pick specifically for growth and revenue expansion. DHR and A also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
TRNS
Transcat, Inc.
The Long-Run Compounder

TRNS is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 7.7% 10Y total return vs JPM's 465.8%
  • 19.2% revenue growth vs DHR's 2.9%
Best for: long-term compounding
TMO
Thermo Fisher Scientific Inc.
The Healthcare Pick

Among these 5 stocks, TMO doesn't own a clear edge in any measured category.

Best for: healthcare exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • PEG 0.81 vs DHR's 35.21
  • Lower P/E (14.4x vs 21.4x), PEG 0.81 vs 1.46
  • 20.4% margin vs TRNS's 2.0%
Best for: income & stability and valuation efficiency
DHR
Danaher Corporation
The Defensive Pick

DHR ranks third and is worth considering specifically for sleep-well-at-night and defensive.

  • Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
  • Beta 0.70, yield 0.7%, current ratio 1.87x
  • Beta 0.70 vs TRNS's 1.35, lower leverage
Best for: sleep-well-at-night and defensive
A
Agilent Technologies, Inc.
The Growth Play

A is the clearest fit if your priority is growth exposure.

  • Rev growth 6.7%, EPS growth 3.2%, 3Y rev CAGR 0.5%
  • 11.1% ROA vs JPM's 1.3%, ROIC 13.5% vs 4.5%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthTRNS logoTRNS19.2% revenue growth vs DHR's 2.9%
ValueJPM logoJPMLower P/E (14.4x vs 21.4x), PEG 0.81 vs 1.46
Quality / MarginsJPM logoJPM20.4% margin vs TRNS's 2.0%
Stability / SafetyDHR logoDHRBeta 0.70 vs TRNS's 1.35, lower leverage
DividendsJPM logoJPM1.9% yield, 15-year raise streak, vs DHR's 0.7%, (1 stock pays no dividend)
Momentum (1Y)JPM logoJPM+21.8% vs DHR's -11.5%
Efficiency (ROA)A logoA11.1% ROA vs JPM's 1.3%, ROIC 13.5% vs 4.5%

TRNS vs TMO vs JPM vs DHR vs A — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
TRNSTranscat, Inc.
FY 2025
Service
65.4%$217M
Distribution Service
34.6%$115M
TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000
DHRDanaher Corporation
FY 2025
Revenue from Contract with Customer, Measurement, Recurring
81.9%$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring
18.1%$4.4B
AAgilent Technologies, Inc.
FY 2025
Agilent CrossLab
41.9%$2.9B
Life Sciences and Applied Markets
39.2%$2.7B
Applied Markets
18.9%$1.3B

TRNS vs TMO vs JPM vs DHR vs A — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGDHR

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 842.9x TRNS's $333M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to TRNS's 2.0%. On growth, TRNS holds the edge at +15.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
RevenueTrailing 12 months$333M$45.2B$280.3B$24.8B$7.2B
EBITDAEarnings before interest/tax$40M$10.5B$81.4B$7.2B$1.8B
Net IncomeAfter-tax profit$7M$6.9B$57.0B$3.7B$1.4B
Free Cash FlowCash after capex$20M$6.7B$100.9B$5.3B$1.3B
Gross MarginGross profit ÷ Revenue+32.6%+39.4%+60.0%+60.7%+53.0%
Operating MarginEBIT ÷ Revenue+4.1%+17.8%+25.9%+21.0%+21.5%
Net MarginNet income ÷ Revenue+2.0%+15.2%+20.4%+14.9%+19.6%
FCF MarginFCF ÷ Revenue+5.9%+14.9%+36.0%+21.4%+17.4%
Rev. Growth (YoY)Latest quarter vs prior year+15.8%+6.2%+3.7%+10.0%
EPS Growth (YoY)Latest quarter vs prior year-56.3%+11.3%+16.0%+9.8%+60.0%
JPM leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 5 of 7 comparable metrics.

At 16.0x trailing earnings, JPM trades at a 90% valuation discount to TRNS's 160.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs DHR's 35.21x — a lower PEG means you pay less per unit of expected earnings growth.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
Market CapShares × price$852M$174.4B$896.0B$127.5B$36.7B
Enterprise ValueMkt cap + debt − cash$976M$205.4B$1.50T$141.3B$38.2B
Trailing P/EPrice ÷ TTM EPS160.11x26.46x16.00x35.73x28.41x
Forward P/EPrice ÷ next-FY EPS est.51.85x18.88x14.40x21.34x21.43x
PEG RatioP/E ÷ EPS growth rate12.53x0.90x35.21x1.93x
EV / EBITDAEnterprise value multiple24.76x18.86x18.36x18.63x21.64x
Price / SalesMarket cap ÷ Revenue2.57x3.91x3.20x5.19x5.28x
Price / BookPrice ÷ Book value/share2.83x3.31x2.47x2.44x5.47x
Price / FCFMarket cap ÷ FCF43.60x27.72x8.88x24.23x31.83x
JPM leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

A leads this category, winning 4 of 9 comparable metrics.

A delivers a 20.8% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $2 for TRNS. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs A's 5/9, reflecting strong financial health.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
ROE (TTM)Return on equity+2.2%+13.2%+15.9%+7.1%+20.8%
ROA (TTM)Return on assets+1.4%+6.4%+1.3%+4.5%+11.1%
ROICReturn on invested capital+2.6%+7.5%+4.5%+5.9%+13.5%
ROCEReturn on capital employed+3.3%+9.1%+8.9%+7.0%+14.5%
Piotroski ScoreFundamental quality 0–956575
Debt / EquityFinancial leverage0.43x0.76x2.60x0.35x0.50x
Net DebtTotal debt minus cash$124M$31.0B$599.0B$13.8B$1.6B
Cash & Equiv.Liquid assets$5M$9.9B$343.3B$4.6B$1.8B
Total DebtShort + long-term debt$129M$40.9B$942.4B$18.4B$3.4B
Interest CoverageEBIT ÷ Interest expense2.81x5.89x0.74x18.13x15.72x
A leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $8,449 for DHR. Over the past 12 months, JPM leads with a +21.8% total return vs DHR's -11.5%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs DHR's -4.5% — a key indicator of consistent wealth creation.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
YTD ReturnYear-to-date+59.7%-20.7%-0.5%-21.7%-5.5%
1-Year ReturnPast 12 months+17.9%+13.4%+21.8%-11.5%+10.0%
3-Year ReturnCumulative with dividends-1.0%-9.5%+138.2%-13.0%+12.0%
5-Year ReturnCumulative with dividends+66.3%+1.4%+118.2%-15.5%-6.9%
10-Year ReturnCumulative with dividends+769.1%+219.0%+465.8%+222.6%+206.2%
CAGR (3Y)Annualised 3-year return-0.3%-3.3%+33.6%-4.5%+3.8%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TRNS and DHR each lead in 1 of 2 comparable metrics.

DHR is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than TRNS's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TRNS currently trades 96.3% from its 52-week high vs TMO's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
Beta (5Y)Sensitivity to S&P 5001.35x0.91x0.94x0.70x1.06x
52-Week HighHighest price in past year$94.76$643.99$337.25$242.80$160.27
52-Week LowLowest price in past year$50.23$385.46$262.71$160.93$108.35
% of 52W HighCurrent price vs 52-week peak+96.3%+72.9%+95.1%+74.2%+81.0%
RSI (14)Momentum oscillator 0–10062.750.859.152.056.1
Avg Volume (50D)Average daily shares traded155K2.0M7.0M4.2M1.9M
Evenly matched — TRNS and DHR each lead in 1 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: TRNS as "Buy", TMO as "Buy", JPM as "Buy", DHR as "Buy", A as "Buy". Consensus price targets imply 35.4% upside for TRNS (target: $124) vs 5.9% for JPM (target: $340). For income investors, JPM offers the higher dividend yield at 1.86% vs TMO's 0.36%.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$123.60$599.70$339.75$231.80$154.75
# AnalystsCovering analysts1042614340
Dividend YieldAnnual dividend ÷ price+0.4%+1.9%+0.7%+0.8%
Dividend StreakConsecutive years of raises081590
Dividend / ShareAnnual DPS$1.69$5.95$1.23$0.99
Buyback YieldShare repurchases ÷ mkt cap+0.1%+1.7%+3.9%+2.4%+1.2%
JPM leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

JPM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). A leads in 1 (Profitability & Efficiency). 1 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...

TRNS vs TMO vs JPM vs DHR vs A: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TRNS or TMO or JPM or DHR or A a better buy right now?

For growth investors, Transcat, Inc.

(TRNS) is the stronger pick with 19. 2% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Transcat, Inc. (TRNS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TRNS or TMO or JPM or DHR or A?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Transcat, Inc. at 160. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Danaher Corporation's 35. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — TRNS or TMO or JPM or DHR or A?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -15. 5% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TRNS returned +769. 1% versus A's +206. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TRNS or TMO or JPM or DHR or A?

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

70β versus Transcat, Inc. 's 1. 35β — meaning TRNS is approximately 92% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TRNS or TMO or JPM or DHR or A?

By revenue growth (latest reported year), Transcat, Inc.

(TRNS) is pulling ahead at 19. 2% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -63. 7% for Transcat, Inc.. Over a 3-year CAGR, TRNS leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TRNS or TMO or JPM or DHR or A?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 1. 6% for Transcat, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 4. 0% for TRNS. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TRNS or TMO or JPM or DHR or A more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Danaher Corporation's 35. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 51. 9x for Transcat, Inc. — 37. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRNS: 35. 4% to $123. 60.

08

Which pays a better dividend — TRNS or TMO or JPM or DHR or A?

In this comparison, JPM (1.

9% yield), A (0. 8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. TRNS does not pay a meaningful dividend and should not be held primarily for income.

09

Is TRNS or TMO or JPM or DHR or A better for a retirement portfolio?

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

70), 0. 7% yield, +222. 6% 10Y return). Both have compounded well over 10 years (DHR: +222. 6%, TRNS: +769. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TRNS and TMO and JPM and DHR and A?

These companies operate in different sectors (TRNS (Industrials) and TMO (Healthcare) and JPM (Financial Services) and DHR (Healthcare) and A (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TRNS is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock; DHR is a mid-cap quality compounder stock; A is a mid-cap quality compounder stock. JPM, DHR, A pay a dividend while TRNS, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.